Saltar al contenido
República del Perú · Observatorio de la producción científica universitaria
OApol.org Observatorio de Inteligencia Científica Universitaria del Perú
OApol.org
Inicio Universidades Publicaciones Investigadores
Repositorios
Tesis y trabajos académicosRevistas
Indicadores
Ranking trimestralRanking por carreraObjetivos de Desarrollo SostenibleReporte OCDERed neuronal 3D
Acerca
MetodologíaPrivacidad

Quality of life and satisfaction after unilateral oncoplastic surgery. Experience of a Latin American cancer hospital

Chávez Díaz M.; Tapia Amaya J.; Díaz Aybar D.; Cueva Pérez M.D.R. · Revista de Senologia y Patologia Mamaria (2023) · DOI: 10.1016/j.senol.2023.100548

Resumen

Introduction: Oncoplastic surgery (COP) has had a great development, allowing safe oncological resections, preventing potential deformities and asymmetries. We evaluated the impact on quality of life in patients with COP level I and II, using the BREAST Q BCT questionnaire and the desire for symmetrization after adjuvant therapy. Methodology: 50 patients diagnosed with breast cancer, treated with unilateral COP (Level I and Level II), were studied during the period between October 2017 and May 2022, to whom the BREAST Q BCT postoperative questionnaire was applied, in addition to survey on the desire for symmetrization. Results: In the domains of the BREAST Q studied, they recorded: “psychosocial well-being” (median of 83), “sexual well-being” (median of 66), “physical well-being” (median of 76), “satisfaction with the operated breast” (median of 80), “satisfaction with the information received” (median of 76) and “satisfaction with the health team” (median of 100). No statistical relationship was found between the variables studied and the median scores of the “satisfaction of operated breast” domain. Only 10% of the patients expressed the desire for symmetrization. Conclusion: The results show high levels of satisfaction in COP level I and II unilateral, having an impact on the quality of life of the patients; expressing the desire for symmetrization, predominant in level II mammoplasties and extreme COP.